A new era for treatment development in HER2-positive breast cancer
Mené sur 36 patientes atteintes d'un cancer du sein HER2+ ER+, cet essai de phase II évalue l'efficacité, notamment du point de vue du changement de l'expression de Ki67 après 16 semaines de traitement, et la toxicité d'un traitement néoadjuvant combinant trastuzumab, pertuzumab, palbociclib et fulvestrant
HER2-positive breast cancer has long been considered a clinically distinct disease, mainly because of the striking efficacy achieved by HER2-targeted treatments in the early and metastatic settings. However, the effectiveness of these therapies has been variable, and the development of different types of treatment resistance reveals the diversity of HER2-positive breast cancers. As part of efforts by the International Cancer Genome Consortium (ICGC) Breast Cancer Working Group, Ferrari and colleagues1 established the gene expression profiles of HER2-positive breast tumours.
The Lancet Oncology , commentaire, 2017